Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis
Background: Targeted therapy with EGFR tyrosine-kinase inhibitors (TKIs) is the preferred first-line treatment for EGFR-mutated advanced non-small-cell lung cancer (NSCLC), but acquired resistance inevitably occurs in almost all responding individuals. Objectives: We aimed to comprehensively review...
Saved in:
| Main Authors: | Wengang Zhang, Jian Xiong, Yujie Li, Jing Nie, Wencheng Zhao, Zhiyi Guo, Xinyue Liu, Qianqian Zhang, Xuyang Chen, Li Ye, Zhimin Chen, Hao Wang, Kandi Xu, Lishu Zhao, Yujin Liu, Lihua Huang, Yuhang Li, Yayi He |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251338046 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01) -
Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01) -
Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitor
by: Krishna Babu Duggirala, et al.
Published: (2025-07-01) -
Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945
by: Yueyang Wang, et al.
Published: (2025-08-01) -
EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
by: Nazia Chaudhary, et al.
Published: (2025-02-01)